Skip to main content

BRIEF RESEARCH REPORT article

Front. Immunol.

Sec. T Cell Biology

Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1560383

This article is part of the Research Topic Mechanisms and Therapeutic Opportunities of T Cell Impairment in Cancer Immunity and Immunotherapy View all 9 articles

Co-expression of B7-H3 and LAG3 represents cytotoxicity of CD4 + T cells in humans

Provisionally accepted
  • 1 Hiroshima University, Hiroshima, Japan
  • 2 Kyushu University, Fukuoka, Fukuoka, Japan

The final, formatted version of the article will be published soon.

    Recent studies have highlighted the potential contribution of CD4 + T cells with cytotoxic activity (CD4 CTLs) to anti-tumor immunity. However, their precise roles remain elusive, partly due to the absence of specific markers defining CD4 CTLs with target-killing potential in humans. We previously demonstrated that Epstein-Barr virus (EBV)-driven immortalized B cell lines efficiently induce human CD4 CTLs with cytotoxic functions comparable to cytotoxic CD8 + T cells (CD8 CTLs). Here we show that EBV-driven CD4 CTLs exhibit prolonged proliferation and sustained cytotoxicity compared with CD8 CTLs, although their cytotoxic function markedly decreased during long-term culture.Comparative transcriptomic analysis of CD4 CTLs with varying cytotoxic activities identified B7-H3 and LAG3 as surface molecules associated with highly cytotoxic CD4 CTLs. Co-expression of B7-H3 and LAG3 correlated with CD107a expression and was observed on CD4 + T cells with enhanced cytotoxic potential in a target-dependent manner but not on CD8 CTLs. Furthermore, B7-H3 + LAG3 + CD4 + T cells were induced during co-culture with bone marrow cells from pediatric patients with Bcell acute lymphoblastic leukemia (B-ALL). These findings suggest that B7-H3 and LAG3 coexpression represents a characteristic feature of functional CD4 CTLs in humans, providing valuable insights into the role of CD4 CTLs in tumor immunity.

    Keywords: tumor immunity, CD4 + cytotoxic T cells, Leukemia, Lymphoma, EB virus, B7-H3

    Received: 14 Jan 2025; Accepted: 10 Feb 2025.

    Copyright: © 2025 Tamura, Ohki, Nagai, Yoshizato, Nishi, Jin, Kitajima, Guo, Ichinohe, Okada, Kawano and Yasuda. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Yohei Kawano, Hiroshima University, Hiroshima, Japan
    Tomoharu Yasuda, Hiroshima University, Hiroshima, Japan

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

    Research integrity at Frontiers

    Man ultramarathon runner in the mountains he trains at sunset

    94% of researchers rate our articles as excellent or good

    Learn more about the work of our research integrity team to safeguard the quality of each article we publish.


    Find out more